Return Peptide Library

Eloralintide

CLevel 1 evidence

Eloralintide

Amylin analog

AI Interpretation of This Peptide Generate Report

Basic Information

Categories

Amylin receptor agonist

Overview

Eli Lilly's once-weekly selective amylin receptor agonist demonstrated significant weight loss results in Phase II trials, with Phase 2025 enrollment beginning at year-end.

Efficacy Rating

Amylin Agonist, Weight Loss, Investigational

Evidence Level

Class C

Evidence Type

No data available

Confidence

No data available

China Regulatory Status

Cosmetic Ingredient Directory

No data available

Food/Supplements

No data available

Medicine

No data available

Similar Peptide Recommendations

ASC36

ASC36

Research on amylin and obesity

Amycretin

Amycretin

Weight loss, in research, GLP-1

Cagrilintide

Cagrilintide

Weight loss, metabolic health, in research

MBX 5765

MBX 5765

Research on amylin, GLP-1

Disclaimer

The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.